close 74% jaeinvestorite kontodest jääb antud teenusepakkuja juures hinnavahelepingutega kauplemisel kahjumisse. Investeerimisega kaasnevad riskid ja need ei ole sobilikud kõigile investoritele. Hinnavahelepingud on keerukad instrumendid, millega kaasneb võimenduse tõttu suur risk kaotada raha kiiresti. 74% jaeinvestorite kontodest jääb antud teenusepakkuja juures hinnavahelepingutega kauplemisel kahjumisse. Palume teil kaaluda, kas hinnavahelepingute süsteem on teile arusaadav ja kas olete valmis võtma riski, mis suure tõenäoususega on kahjumlik.
Change languageEesti
Ülevaade
Kodu・Aktsiate loetelu・BioArctic AB
Search

BioArctic AB

Suletud

265.6 -0.75

Hinna uuendus 11. nov 2025, 16:24 UTC

OstaMüü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

255

Max

269

Põhinäitajad

By Trading Economics

Sissetulek

-896M

179M

Müük

-897M

392M

P/E

Sektori keskmine

24.328

77.256

Aktsiakasum

1.09

Kasumimarginaal

45.668

Töötajad

119

EBITDA

-893M

188M

Turustatistika

By TradingEconomics

Turukapital

5.1B

26B

Eelmine avamishind

266.35

Eelmine sulgemishind

265.6

BioArctic AB Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

11. nov 2025, 22:23 UTC

Omandamised, ülevõtmised, äriostud

Mineral Resources Sells Stake in Lithium Mines to Posco For $765 Million

DJ

Loe

11. nov 2025, 22:21 UTC

Tulu

Aristocrat Boosts Dividend as Annual Profit Rises 12%

DJ

Loe

11. nov 2025, 23:52 UTC

Market Talk

Gold Rises Amid Fed Rate-Cut Prospects -- Market Talk

DJ

Loe

11. nov 2025, 23:44 UTC

Tulu

Singtel's 1H Net Profit Surges

DJ

Loe

11. nov 2025, 23:42 UTC

Market Talk

Nikkei May Trade Rangebound Amid Caution over U.S. Econ Strength -- Market Talk

DJ

Loe

11. nov 2025, 23:18 UTC

Tulu

Singtel: Expects FY Operating Company EBIT to Grow Between High Single Digits and Low Double Digits Vs. Earlier Guidance of High Single-Digit Growth >Z74.SG

DJ

Loe

11. nov 2025, 23:15 UTC

Tulu

Singtel: Interim Dividend of 8.2 Singapore Cents per Share, up 17% >Z74.SG

DJ

Loe

11. nov 2025, 23:14 UTC

Tulu

Singtel 1H Underlying Net Profit S$1.35B, Up 14% >Z74.SG

DJ

Loe

11. nov 2025, 23:12 UTC

Tulu

Singtel 1H Net Exceptional Gain of S$2.05B >Z74.SG

DJ

Loe

11. nov 2025, 23:11 UTC

Tulu

Singtel 1H Net S$3.40B Vs. Net S$1.23B >Z74.SG

DJ

Loe

11. nov 2025, 23:10 UTC

Tulu

Singtel 1H Rev S$6.91B Vs. S$6.99B >Z74.SG

DJ

Loe

11. nov 2025, 23:04 UTC

Market Talk

RBA Will Sharply Focus On Australian Jobs Report -- Market Talk

DJ

Loe

11. nov 2025, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

DJ

Loe

11. nov 2025, 21:50 UTC

Market Talk
Tulu

Health Care Roundup: Market Talk

DJ

Loe

11. nov 2025, 21:46 UTC

Market Talk
Omandamised, ülevõtmised, äriostud

Private Equity Can Benefit From 'Deal-Friendly' Antitrust Policies -- Market Talk

DJ

Loe

11. nov 2025, 21:41 UTC

Tulu

Aristocrat: Continues to Actively Pursue Strategic M&A Opportunities

DJ

Loe

11. nov 2025, 21:40 UTC

Tulu

Aristocrat: Expects to Deliver Npata Growth Over FY 2026 on a Constant Currency Basis

DJ

Loe

11. nov 2025, 21:39 UTC

Tulu

Aristocrat: Interactive Delivered Revenue Growth Mainly Due to Inclusion of NeoGames

DJ

Loe

11. nov 2025, 21:39 UTC

Tulu

Aristocrat: Key Social Casino Franchises Continued to Outperform Market

DJ

Loe

11. nov 2025, 21:39 UTC

Tulu

Aristocrat: Gaming Unit Continued to Deliver Market Share Gains

DJ

Loe

11. nov 2025, 21:38 UTC

Tulu

Aristocrat: FY Normalized Npata Up 9% in Constant Currency

DJ

Loe

11. nov 2025, 21:38 UTC

Tulu

Aristocrat: Final Dividend 49 Australian Cents/Share

DJ

Loe

11. nov 2025, 21:37 UTC

Tulu

Aristocrat: FY Statutory Net Profit from Continuing Ops A$1.18 Bln, Up 2.9%

DJ

Loe

11. nov 2025, 21:36 UTC

Tulu

Aristocrat: FY Normalized Operating Revenue A$6.3 Bln, Up 11%

DJ

Loe

11. nov 2025, 21:35 UTC

Tulu

Aristocrat: FY Normalized Npata A$1.55 Bln, Up 12.2%

DJ

Loe

11. nov 2025, 21:35 UTC

Tulu

Alcon 3Q Adj EPS 79c >ALC

DJ

Loe

11. nov 2025, 21:35 UTC

Tulu

Alcon 3Q Rev $2.61B >ALC.EB

DJ

Loe

11. nov 2025, 21:35 UTC

Tulu

Alcon Backs 2025 EPS $3.05-EPS $3.15 >ALC.EB

DJ

Loe

11. nov 2025, 21:35 UTC

Tulu

Alcon 3Q EPS 48c >ALC.EB

DJ

Loe

11. nov 2025, 21:34 UTC

Tulu

Alcon Backs 2025 Adj EPS $3.05-Adj EPS $3.15 >ALC

DJ

Loe

BioArctic AB Prognoos

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest BioArctic AB

BioArctic AB (publ) develops biological drugs for patients with disorders of the central nervous system in Sweden. The company develops Lecanemab, Lecanemab AHEAD 3-45, and Lecanemab Back-up for the treatment of Alzheimer's disease. In addition, the company develops AD-BT2802 and AD-BT2803 drug projects against Alzheimer's disease that are being combined with blood-brain barrier technology and Brain Transporter to promote uptake of antibodies into the brain. Further, it develops BAN1503, BAN2802, BAN2803, and AD2603 for the treatment of Alzheimer's disease; ND-BT3814, ND3014, andGD-BT6822 for the treatment of neurodegenerative disease; and PD1601, PD-BT2238, and PD1602 for the treatment of Parkinson's disease. It has research collaboration agreement with Eisai and AbbVie. The company was formerly known as BioArctic Neuroscience AB and changed its name to BioArctic AB (publ) in 2016. BioArctic AB (publ) was incorporated in 2000 and is based in Stockholm, Sweden.
help-icon Live chat